LGALS9 and systemic lupus erythematosus: In a recent study, Panda et al. demonstrated that treatment of BXSB/MpJ and (NZB × NZW)F1 lupus-prone mice with Gal-9 before symptoms manifests diminishes the probability of developing pathology, including tissue inflammation and splenomegaly associated with disease onset (70).